A study measuring specific serum metabolites identified by mass spectrometry plus the presence of elevated AST, fasting insulin and the PNPLA3 genotype was found to be good at discerning NASH from NAFL in a northern European cohort [14]. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatohepatitis.